Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Unknown unknown |
Therapy | Doxorubicin + DT2216 |
Indication/Tumor Type | triple-receptor negative breast cancer |
Response Type | not applicable |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | triple-receptor negative breast cancer | not applicable | Doxorubicin + DT2216 | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of DT2216 to Adriamycin (doxorubicin) treatment resulted in decreased viability of a triple-negative breast cancer cell line in culture (PMID: 31792461). | 31792461 |
PubMed Id | Reference Title | Details |
---|---|---|
(31792461) | A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. | Full reference... |